+ Watch ALIM
on My Watchlist
This stock has been growing over the past few weeks. It seems that the growth is constant and should continue to grow over the next few weeks.
Alimera is one of those stocks that keeps on punishing me, in CAPS and in real-life. The most recent insult was an attempt to close an underperform pitch with a nice winning score that suddenly turned into a loser after the stock spiked 10% in a few minutes for absolutely no reason after I closed the pick.I can't accept defeat, so I'm coming back for more punishment. I see Iluvien as a dead end commercially, and Alimera is in serious trouble since they don't have much of a pipeline after that. Getting a drug approved in the EU and getting it reimbursed by the governments are two different things. Iluvien seems to have suffered a final rejection at the hands of UK's NICE and will have to seek back door reimbursement through a Patient Access Scheme, which doesn't sound very promising. The Iluvien launch will occur some time this quarter in Germany, but I haven't seen any documentation to indicate that the notoriously intransigent German utilization committee IQWiG has rendered an opinion on reimbursement. The UK has clearly set a painful precedent that the other socialized systems will be glad to follow. Meanwhile, the cash position was only 17M at the end of Q3 and burn is likely to grow with the challenges of seven launches in hostile European environments.
went up 244% for portefeille.
This is a huge need in Ophthalmology patient care. Patients are enduring numerous injections into the eye to decrease edema and the progressive damage it can create. This time-released med will last a long time while decreasing risk and cost to the patient.
I am still underwater here, but you never know...Choo...choo... : )
There are currently 2200 ALIM shares in my "fund" with break-even of around 5.81 USD.http://caps.fool.com/Blogs/fund-trades/678775.
European approval will help lift it from the basement of FDA rejection!
Diabetes Diabetes Diabetes. americans are unhealthy
First FDA rejection was fairly benign. Investors will come back as second decision approaches.
oversold on FDA news
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions